Step 1

Step 2

We feature 613 specialists in this practice area.

Step 3

We identify specialists in 48 countries.

Featured Articles
Analysis
Experts
Firms

Featured Articles: Life Sciences

Roundtable: Life Sciences

The International Who’s Who of Life Sciences Lawyers has brought together five of the leading practitioners in the world to discuss key issues facing lawyers today.

Pharmaceutical Pricing and Reimbursement in Canada: An Overview for Innovative Drug Manufacturers

Penny S Bonner - Ogilvy Renault LLP

Jill M Daley - Ogilvy Renault LLP

The pricing and reimbursement of innovative pharmaceuticals in Canada is controlled at three levels: by the federal Patented Medicine Prices Review Board, by the 17 federal, provincial and territorial public drug plans and by the Common Drug Review. This system means that an innovative manufacturer must obtain the approval of 19 different bodies for the price of a new drug in Canada.

The Supplementary Protection Certificate for Medicinal Products: An Update

Carla Schoonderbeek - NautaDutilh

Since its introduction in 1992 the Supplementary Protection Certificate (SPC) has been the object of litigation in many jurisdictions. The case law has been able to clarify the use of the regulations establishing the SPC, but some issues still have not been resolved.

Life Science patent litigation

Ina vom Feld

Wolfgang von Meibom

The framework of life science patent litigation is exceptional in various ways.

Information exchange or promotion - The commission's proposal on information to patients on prescription-only medicinal products

Ian Dodds-Smith

Silvia Valverde - Arnold & Porter (UK) LLP

Society's interest in health issues has greatly increased in recent years with patients becoming ever more health conscious. Patients want to be informed of both established treatments and treatments under research. Many have access to detailed information from a variety of sources through the internet.

Page

2 pages Search

Analysis: Life Sciences

Research Trends and Conclusions: Life Sciences 2012

This edition features more lawyers in a greater number of jurisdictions than its predecessors. The expansion attests to the continuing leaps in sophistication and geographical spread the discipline has undergone in the past year, despite the travails of the global economy in general and life sciences companies in particular.

Most Highly Regarded Firms: Life Sciences 2012

In this section we analyse the findings of our research in greater depth to identify the firms and practitioners who stand out worldwide.

Research Trends and Conclusions: Life Sciences 2011

With the benefit of over 14 years of research and thousands of votes from clients and private practitioners, Who’s Who Legal takes a closer look at developing trends in the life sciences legal marketplace worldwide.

Most Highly Regarded Firms: Life Sciences 2011

After months of investigation in to the life sciences legal market, our research selects 453 highly accomplished practitioners, praised for their contentious, transactional and regulatory expertise.

Most Highly Regarded Firms: Life Sciences 2010

This second edition of The International Who’s Who of Life Sciences Lawyers recognises 461 practitioners specialising in product liability, regulatory, transactional and intellectual property work for pharmaceutical and biotechnology companies.

Research Trends and Conclusions: Life Sciences 2010

Richard Woolley - Who's Who Legal

The life sciences sector enjoyed mixed fortunes over the past year. A marked increase in M&A among pharmaceutical companies was accompanied by lack of investment and, in some cases, insolvency in biotechnology companies.

Life Sciences